Skip to main content
Wiley - PMC COVID-19 Collection logoLink to Wiley - PMC COVID-19 Collection
. 2020 Jul 14;105(5):519–523. doi: 10.1111/ejh.13478

Sickle cell trait and the potential risk of severe coronavirus disease 2019—A mini‐review

Tawakalitu Abosede Kehinde 1, Mayowa Azeez Osundiji 2,
PMCID: PMC7361772  PMID: 32589774

Abstract

Coronavirus Disease 2019 (COVID‐19) pandemic is a rapidly evolving public health problem. The severity of COVID‐19 cases reported hitherto has varied greatly from asymptomatic to severe pneumonia and thromboembolism with subsequent mortality. An improved understanding of risk factors for adverse clinical outcomes may shed some light on novel personalized approaches to optimize clinical care in vulnerable populations. Emerging trends in the United States suggest possibly higher mortality rates of COVID‐19 among African Americans, although detailed epidemiological study data is pending. Sickle cell disease (SCD) disproportionately affects Black/African Americans in the United States as well as forebearers from sub‐Saharan Africa, the Western Hemisphere (South America, the Caribbean, and Central America), and some Mediterranean countries. The carrier frequency for SCD is high among African Americans. This article underscores the putative risks that may be associated with COVID‐19 pneumonia in sickle cell trait as well as potential opportunities for individualized medical care in the burgeoning era of personalized medicine.

Keywords: acute chest syndrome, coronavirus disease 2019, sickle cell disease, sickle cell trait, Thromboembolism, Vaso‐Occlusive Crisis (VOC)

1. INTRODUCTION

Following the emergence of Coronavirus Disease 2019 (COVID‐19) in Wuhan (China) around December 2019, 1 the infection has become a pandemic, decimating over three hundred thousand globally. 2 The severity of COVID‐19 cases reported hitherto has varied greatly from asymptomatic to severe pneumonia and thromboembolism, accompanied by overt respiratory failure with subsequent mortality. 3 , 4 , 5 As the COVID‐19 pandemic continues to evolve, potential risk factors that may predispose individuals to fatal outcomes are increasingly becoming topical. There are ongoing epidemiological investigations and discussions of potentially at‐risk populations and ethnicities. 6 , 7 An improved understanding of the risk factors as well as clinical course for severe COVID‐19 may shed some light on novel personalized approaches to optimize clinical care and outcomes.

Emerging trends in the United States suggest possibly higher mortality rates of COVID‐19 among African Americans, 8 , 9 although epidemiological study data with adequate denominator 10 across board is pending. There is no doubt that socio‐economic determinants of health play crucial roles in health inequities and disease trajectory. 11 Nevertheless, interplay of genetic and environmental factors contributes to overall clinical outcomes in a substantial burden of human diseases. 12 , 13 , 14 , 15 , 16 , 17 Sickle cell disease (SCD) disproportionately affects Black/African Americans in the United States as well as forebearers from sub‐Saharan Africa, the Western Hemisphere (South America, the Caribbean, and Central America), and some Mediterranean countries. 18 , 19 , 20 Increasing evidence suggests that COVID‐19 pneumonia can cause acute chest syndrome (ACS), a potentially life‐threatening complication in SCD. 21 , 22 , 23 These observations raise questions on the potential contributions of SCD‐related complications, for instance thromboembolism to the severity of COVID‐19. Increasing evidence suggests a higher risk of venous thromboembolism in COVID‐19, 3 , 4 , 5 prompting ongoing considerations and potential applications of prophylactic anticoagulation 24 and therapeutic thrombolysis. 25

Being the carrier state for an autosomal recessive genetic disorder, sickle cell trait is frequently perceived to be a relatively benign condition; however, this remains controversial. 26 , 27 , 28 , 29 , 30 Conditions of increased oxygen demands may trigger sickle‐related complications in heterozygotes. 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 COVID‐19 causes severe pneumonia in at‐risk individuals resulting in an increased oxygen demand. Yet, the notion that COVID‐19 associated pneumonia may result in poor clinical outcomes in sickle cell trait if unrecognized is less discussed. This mini‐review highlights the putative risks of severe COVID‐19 in SCD and sickle cell trait, with a focus on the risks associated with the heterozygous state.

2. EPIDEMIOLOGY AND MOLECULAR PATHOGENESIS OF SICKLE CELL TRAIT

Sickle cell trait affects approximately 300 million people globally. 45 Owing to its protective effects against severe malaria, sickle cell trait confers an evolutionary survival advantage. 46 The highest prevalence of sickle cell trait is in Africa and among people of African descent across the world. 18 , 47 In the United States, national estimates of the sickle cell trait prevalence from Newborn Screening data suggest about 1.5% with about 8% prevalence among African Americans, almost 3 million individuals. 48 About 1%‐3% of the European population carries a gene mutation for hemoglobinopathy, particularly sickle cell trait. 49 , 50 , 51 , 52 Approximately 5% of the world carry a significant hemoglobin gene variant. 52 A recent global meta‐estimate of birth prevalence of SCD was approximately 112 per 100 000 live births with about 10 folds higher birth prevalence in Africa, 1125 per 100 000. 18 , 47

Being the heterozygous state, red blood cells in sickle cell trait have one copy of normal adult hemoglobin (Hb) denoted as HbA and one copy of mutant Hb (HbS) resulting in Hb genotype of HbAS. 53 HbS results from a missense mutation causing amino acid substitution whereby valine replaces glutamic acid in the 6th codon of the β chain. 54 , 55 The presence of HbA attenuates HbS phenotype, reducing the probability of polymer formation; hence, normal hematological parameters are observed in the majority of individuals with sickle cell trait. 54 Nevertheless, cumulative evidence suggests that hypoxia may trigger sickle‐related complications such as splenic infarction, thromboembolism, papillary necrosis, exertional rhabdomyolysis, and death in sickle cell trait. 26 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 43 , 44

3. COVID‐19 PNEUMONIA IN SCD: POTENTIAL RELEVANCE TO SICKLE CELL TRAIT

As of May 16, 2020, 15 SCD patients with COVID‐19 have been reported in the clinical scientific literature indexed in PubMed. 56 These studies are summarized in Table 1. Beerkens et al 57 described the first documented case of SCD patient who developed ACS in the setting of COVID‐19. The index case was on maintenance hydroxyurea therapy for SCD. He was initially started on hydroxychloroquine for severe COVID‐19 pneumonia. He later developed ACS, requiring urgent exchange red blood cell transfusion. Nur et al 58 observed ACS in two SCD patients who presented with VOC. Subsequently, a case series by Hussain and colleagues demonstrated a milder COVID‐19 course in four SCD patients, who seemed to have benefited from early risk stratification and initiation of treatment. 59 A larger case series of 10 SCD patients described 6 confirmed cases of COVID‐19, one of which was fatal. 23 There are two independent case reports of patients with severe COVID‐19 who responded well to tocilizumab. 21 , 22 The dataset on COVID‐19 in SCD patients continues to evolve.

Table 1.

Summary of Published Cases of COVID‐19 in SCD

Reference Age (years)/Gender (M/F) if Known Complications of SCD during COVID‐19 Main treatment Reported outcome
Beerkens et al 57 21/M VOC, ACS Red blood cell (RBC) exchange transfusion Favorable
Nur et al 58 24/M VOC, ACS Oxygen and opioid therapy Favorable
Nur et al 58 20/F VOC Opioid therapy Favorable
De Luna et al 21 45/M ACS IV tocilizumab, RBC exchange transfusion Favorable
Hussain et al 59 32/M VOC,? ACS RBC exchange transfusion, intubation, ICU Favorable
Hussain et al 59 37/F VOC IV fluids and opioid Favorable
Hussain et al 59 22/F Suspected ACS Ceftriaxone, IV opioid Favorable
Hussain et al 59 41/M VOC IV fluids and opioid Favorable
Odiѐvre et al 22 16/F ACS and PE Non‐invasive ventilation, RBC exchange transfusion, ICU Favorable
a McCloskey et al 23 57/unknown Extremely Unwell Palliation Fatal
a McCloskey et al (5 additional cases) 23 Unknown range VOC Oxygen and analgesic therapy Favorable

Abbreviations: ACS, Acute Chest Syndrome; F, Female; ICU, Intensive Care Unit; IV, Intravenous; M, Male; PE, Pulmonary Embolism; VOC, Vaso‐Occlusive Crisis.

a

Limited information available, article is in press.

Although ACS has been reported in a few patients with sickle cell trait, 60 , 61 it appears to be exceedingly rare. An increased risk of thromboembolism in sickle cell carriers seems to be a better recognized sickling complication in heterozygotes. 62 , 63 , 64 , 65 , 66 The risk of hypercoagulability in sickle cell carriers is a subject of active investigations and discussions. 66 , 67 , 68 A prospective study of African Americans demonstrated a 2‐fold increase in the risk of pulmonary embolism in carriers of sickle cell trait. 63 A recent study demonstrated an increased risk of ischemic stroke in individuals who carry sickle cell trait and have concomitant chronic kidney disease. 69 Likewise, sickle cell trait has been associated with an increased risk of coronary artery diseases in African American men who have chronic kidney diseases. 70 The potential contributions of thrombosis related complications of sickle cell trait to the severity of COVID‐19 necessitate further studies particularly due to the higher risk of thromboembolism in COVID‐19. 3 , 4 , 5

Although the risk of COVID‐19 induced complications in SCD is increasingly becoming topical, the potential risk in sickle cell trait warrants consideration given the greater prevalence of the heterozygous state. Healthcare providers are likely to be on the lookout for complications in SCD patients with COVID‐19 pneumonia, whereas individuals with sickle cell trait may be at an increased risk of unrecognized COVID‐19 induced sickle‐related complications. Publicizing these potential complications in carriers may help healthcare providers to include sickling complications in their differential diagnosis when assessing individuals who are from ethnicities with a high prevalence of sickle cell trait. This may facilitate prompt recognition of at‐risk individuals and the provision of individualized care for instance: anticoagulation, 3 , 4 oxygen therapy, 59 blood transfusion, 57 , 58 red blood cell exchange transfusion, 57 , 71 or extracorporeal membrane oxygenation 72 , 73 , 74 when necessary. Individuals who have sickle cell trait and are aware of their HbS genotype could be encouraged to self‐identify when presenting to healthcare providers for COVID‐19 assessment. Increasing the public awareness of sickle‐related complications may also embolden individuals who are aware of their carrier status to seek medical assessment early for COVID‐19. Recent prenatal research data suggest that many sickle cell carriers may not view SCD as a severe disorder 75 ; therefore, it is possible that individuals who have sickle cell trait may benefit from an improved awareness of sickle‐related complications, particularly during the COVID‐19 pandemic.

4. CONCLUSIONS

As highlighted by the medical literature, sickle cell trait potentially increases the risk(s) of hypercoagulability. 30 , 63 , 64 , 65 , 66 During intercurrent COVID‐19, this may lead to poor clinical outcomes. There is no reported case of COVID‐19 in sickle cell trait in the clinical scientific literature as of May 16, 2020. 56 This mini‐review is describing the putative risks to patients with COVID‐19 who may have happened to be sickle cell carriers. It is pertinent to acknowledge that there is no evidence of cause‐effect relationship(s) for the hypothesized association between sickle cell trait and COVID‐19 thus far. Although there is always the limitation of generalizability of risk, an improved awareness of the potential risk of sickle‐related complications in carriers may translate into reduced morbidity and perhaps mortality among vulnerable communities in the evolving COVID‐19 pandemic.

The high prevalence of sickle cell trait among African Americans raises fundamental clinical scientific questions on the potential roles of hemoglobin genotype in COVID‐19 severity considering the mortality trends. Genetic factors predisposing individuals to an increased risk of COVID‐19 mortality continue to be subjects of active investigations. In addition to genes and pathways that are directly targeted by COVID‐19, hemoglobin genotype may be a less evident marker of risk for COVID‐19 severity. Further molecular epidemiological analysis of COVID‐19 disease course and hemoglobin genotype in African Americans are recommended to delineate the potential risks. Given the prevalence among African Americans, strategies to improve awareness of possible risks during COVID‐19 pneumonia in sickle cell trait are suggested to individualize medical care in the burgeoning era of personalized medicine.

Kehinde TA, Osundiji MA. Sickle cell trait and the potential risk of severe coronavirus disease 2019—A mini‐review. Eur J Haematol. 2020;105:519–523. 10.1111/ejh.13478

REFERENCES

  • 1. Liu W, Zhang Q, Chen J, et al. Detection of Covid‐19 in children in Early January 2020 in Wuhan, China. N Engl J Med. 2020;382(14):1370‐1371. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. https://coronavirus.jhu.edu/map.html. John Hopkins Human Resources Center COVID‐19 Map. 2020. in press.
  • 3. Connors JM, Levy JH. COVID‐19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033‐2040. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Gris JC, Perez‐Martin A, Quere I, Sotto A. COVID‐19 associated coagulopathy: The crowning glory of thrombo‐inflammation concept. Anaesth Crit Care Pain Med. 2020. in press. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Inciardi RM, Adamo M, Lupi L, et al. Characteristics and outcomes of patients hospitalized for COVID‐19 and cardiac disease in Northern Italy. Eur Heart J. 2020;41(19):1821‐1829. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Chow N, Fleming‐Dutra K, Gierke R, et al. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 — United States, February 12–March 28, 2020. MMWR. Morb Mortal Wkly Rep. 2020;69(13):382‐386. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Bialek S, Gierke R, Hughes M, McNamara LA, Pilishvili T, Skoff T. Coronavirus disease 2019 in children — United States, February 12–April 2, 2020. MMWR. Morb Mortal Wkly Rep. 2020;69(14):422‐426. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Yancy CW. COVID‐19 and African Americans. JAMA. 2020;323(19):1891. [DOI] [PubMed] [Google Scholar]
  • 9. Fouad MN, Ruffin J, Vickers SM. COVID‐19 is out of proportion in African Americans. This will come as no surprise. Am J Med. 2020. in press. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Gaye B, Fanidi A, Jouven X. Denominator matters in estimating COVID‐19 mortality rates. Eur Heart J. 2020. in press. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Moor I, Spallek J, Richter M. Explaining socioeconomic inequalities in self‐rated health: a systematic review of the relative contribution of material, psychosocial and behavioural factors. J Epidemiol Community Health. 2017;71(6):565‐575. [DOI] [PubMed] [Google Scholar]
  • 12. Lindgren M, Samuelsson J, Nilsson L, et al. Genetic variation in IL28B (IFNL3) and response to interferon‐alpha treatment in myeloproliferative neoplasms. Eur J Haematol. 2018;100(5):419‐425. [DOI] [PubMed] [Google Scholar]
  • 13. Umeukeje EM, Young BA. Genetics and ESKD disparities in African Americans. Am J Kidney Dis. 2019;74(6):811‐821. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Boddu PC, Kadia TM. Molecular pathogenesis of acquired aplastic anemia. Eur J Haematol. 2019;102(2):103‐110. [DOI] [PubMed] [Google Scholar]
  • 15. Shallis RM, Ahmad R, Zeidan AM. The genetic and molecular pathogenesis of myelodysplastic syndromes. Eur J Haematol. 2018;101(3):260‐271. [DOI] [PubMed] [Google Scholar]
  • 16. Braun L, Fausto‐Sterling A, Fullwiley D, et al. Racial categories in medical practice: how useful are they? PLoS Medicine. 2007;4(9):e271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Campbell AD, Colombatti R, Andemariam B, et al. Analysis of racial and ethnic backgrounds within the CASiRe International cohort of sickle cell disease patients: implications for disease phenotype and clinical research. J Racial Ethn Health Disparities. 2020. in press. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Wastnedge E, Waters D, Patel S, et al. The global burden of sickle cell disease in children under five years of age: a systematic review and meta‐analysis. J Glob Health. 2018;8(2):e021103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Bakr S, Khorshied M, Talha N, et al. Implication of HMOX1 and CCR5 genotypes on clinical phenotype of Egyptian patients with sickle cell anemia. Ann Hematol. 2019;98(8):1805‐1812. [DOI] [PubMed] [Google Scholar]
  • 20. Russo G, De Franceschi L, Colombatti R, et al. Current challenges in the management of patients with sickle cell disease ‐ A report of the Italian experience. Orphanet J Rare Dis. 2019;14(1):120. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. De Luna G, Habibi A, Deux JF, et al. Rapid and severe Covid‐19 pneumonia with severe acute chest syndrome in a sickle cell patient successfully treated with tocilizumab. Am J Hematol. 2020;95(7):876‐878. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Odievre MH, de Marcellus C, Ducou Le Pointe H, et al. Dramatic improvement after tocilizumab of severe COVID‐19 in a child with sickle cell disease and acute chest syndrome. Am J Hematol. 2020:e25855. in press. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. McCloskey KA, Meenan J, Hall R, Tsitsikas DA. COVID‐19 infection and sickle cell disease: a UK centre experience. Br J Haematol. 2020:e16779. in press. [DOI] [PubMed] [Google Scholar]
  • 24. Hippensteel JA, LaRiviere WB, Colbert JF, Langouet‐Astrie CJ, Schmidt EP. Heparin as a therapy for COVID‐19: current evidence and future possibilities. Am J Physiol Lung Cell Mol Physiol. 2020. in press. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Poor HD, Ventetuolo CE, Tolbert T, et al. COVID‐19 critical illness pathophysiology driven by diffuse pulmonary thrombi and pulmonary endothelial dysfunction responsive to thrombolysis. Clin Transl Med. 2020. in press. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Fernando C, Mendis S, Upasena AP, Costa YJ, Williams HS, Moratuwagama D. Splenic syndrome in a young man at high altitude with undetected sickle cell trait. J Patient Exp. 2018;5(2):153‐155. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Kotila TR. Sickle cell trait: a Benign state? Acta Haematol. 2016;136(3):147‐151. [DOI] [PubMed] [Google Scholar]
  • 28. Key NS, Derebail VK. Sickle‐cell trait: novel clinical significance. Hematology Am Soc Hematol Educ Program. 2010;2010:418‐422. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. Xu JZ, Thein SL. The carrier state for sickle cell disease is not completely harmless. Haematologica. 2019;104(6):1106‐1111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Naik RP, Smith‐Whitley K, Hassell KL, et al. Clinical outcomes associated with sickle cell trait: a systematic review. Ann Intern Med. 2018;169(9):619‐627. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. Kerle KK, Nishimura KD. Exertional collapse and sudden death associated with sickle cell trait. Mil Med. 1996;161(12):766‐767. [PubMed] [Google Scholar]
  • 32. Holmes PS, Kerle KK, Seto CK. Sickle cell trait and sudden death in athletes. Am Fam Physician. 1998;58(8):1760‐1761. [PubMed] [Google Scholar]
  • 33. Adams JQ. Sudden death in pregnancy due to the sickle cell trait. South Med J. 1957;50(7):898‐901. [DOI] [PubMed] [Google Scholar]
  • 34. Biedrzycki O, Gillespie H, Lucas S. Sudden death in a patient newly diagnosed with diabetes having hyperosmolar non‐ketotic acidosis with sickle cell trait. J Clin Pathol. 2006;59(8):882‐883. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35. Browne RJ. Sickle cell trait and sudden death. Sports Med. 1994;18(6):373‐374. [DOI] [PubMed] [Google Scholar]
  • 36. Buchanan BK, Siebert DM, Zigman Suchsland ML, et al. Sudden death associated with sickle cell trait before and after mandatory screening. Sports Health. 2020;12(3):241‐245. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37. Davis AM. Sickle‐cell trait as a risk factor for sudden death in physical training. N Engl J Med. 1988;318(12):787. [DOI] [PubMed] [Google Scholar]
  • 38. Diggs LW. The sickle cell trait in relation to the training and assignment of duties in the armed forces: III. Hyposthenuria, hematuria, sudden death, rhabdomyolysis, and acute tubular necrosis. Aviat Space Environ Med. 1984;55(5):358‐364. [PubMed] [Google Scholar]
  • 39. Murray MJ, Evans P. Sudden exertional death in a soldier with sickle cell trait. Mil Med. 1996;161(5):303‐305. [PubMed] [Google Scholar]
  • 40. Evans P, Murray MJ. Sudden exertional death and sickle cell trait. Am Fam Physician. 1997;55(3):784. [PubMed] [Google Scholar]
  • 41. Francis CK, Bleakley DW. The risk of sudden death in sickle cell trait: noninvasive assessment of cardiac response to exercise. Cathet Cardiovasc Diagn. 1980;6(1):73‐80. [DOI] [PubMed] [Google Scholar]
  • 42. Gozal D, Lorey FW, Chandler D, et al. Incidence of sudden infant death syndrome in infants with sickle cell trait. J Pediatr. 1994;124(2):211‐214. [DOI] [PubMed] [Google Scholar]
  • 43. Loosemore M, Walsh SB, Morris E, Stewart G, Porter JB, Montgomery H. Sudden exertional death in sickle cell trait. Br J Sports Med. 2012;46(5):312‐314. [DOI] [PubMed] [Google Scholar]
  • 44. Small E. Sickle cell trait and sudden death. Pediatr Ann. 2003;32(11):757‐759. [DOI] [PubMed] [Google Scholar]
  • 45. Grant AM, Parker CS, Jordan LB, et al. Public health implications of sickle cell trait: a report of the CDC meeting. Am J Prev Med. 2011;41(6 Suppl 4):S435‐S439. [DOI] [PubMed] [Google Scholar]
  • 46. Elguero E, Delicat‐Loembet LM, Rougeron V, et al. Malaria continues to select for sickle cell trait in Central Africa. Proc Natl Acad Sci USA. 2015;112(22):7051‐7054. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47. Makani J, Ofori‐Acquah SF, Nnodu O, Wonkam A, Ohene‐Frempong K. Sickle cell disease: new opportunities and challenges in Africa. ScientificWorldJournal. 2013;2013:e193252. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48. Therrell BL Jr, Lloyd‐Puryear MA, Eckman JR, Mann MY. Newborn screening for sickle cell diseases in the United States: a review of data spanning 2 decades. Semin Perinatol. 2015;39(3):238‐251. [DOI] [PubMed] [Google Scholar]
  • 49. Kunz JB, Awad S, Happich M, et al. Significant prevalence of sickle cell disease in Southwest Germany: results from a birth cohort study indicate the necessity for newborn screening. Ann Hematol. 2016;95(3):397‐402. [DOI] [PubMed] [Google Scholar]
  • 50. Giambona A, Vinciguerra M, Cannata M, et al. The genetic heterogeneity of beta‐globin gene defects in Sicily reflects the historic population migrations of the island. Blood Cells Mol Dis. 2011;46(4):282‐287. [DOI] [PubMed] [Google Scholar]
  • 51. Schiliro G, Mirabile E, Testa R, Russo‐Mancuso G, Dibenedetto SP. Presence of hemoglobinopathies in Sicily: a historic perspective. Am J Med Genet. 1997;69(2):200‐206. [DOI] [PubMed] [Google Scholar]
  • 52. Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ. 2008;86(6):480‐487. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53. Antwi‐Baffour S, Asare RO, Adjei JK, Kyeremeh R, Adjei DN. Prevalence of hemoglobin S trait among blood donors: a cross‐sectional study. BMC Res Notes. 2015;8:583. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54. Murayama M. The molecular mechanism of human red cell sickling. West Afr J Pharmacol Drug Res. 1974;1(1):6P‐14P. [PubMed] [Google Scholar]
  • 55. Murayama M. Molecular mechanism of red cell "sickling". Science. 1966;153(3732):145‐149. [DOI] [PubMed] [Google Scholar]
  • 56. PubMed . https://pubmed.ncbi.nlm.nih.gov/. Accessed May 16, 2020.
  • 57. Beerkens F, John M, Puliafito B, Corbett V, Edwards C, Tremblay D. COVID‐19 pneumonia as a cause of acute chest syndrome in an adult sickle cell patient. Am J Hematol. 2020;95(7):E154‐E156. [DOI] [PubMed] [Google Scholar]
  • 58. Nur E, Gaartman AE, van Tuijn CFJ, Tang MW, Biemond BJ. Vaso‐occlusive crisis and acute chest syndrome in sickle cell disease due to 2019 novel coronavirus disease (COVID‐19). Am J Hematol. 2020;95(6):725‐726. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59. Hussain FA, Njoku FU, Saraf SL, Molokie RE, Gordeuk VR, Han J. COVID‐19 infection in patients with sickle cell disease. Br J Haematol. 2020;189(5):851‐852. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60. Steigman CK, McElderry J. A fatal case of acute chest syndrome in a patient with undiagnosed sickle cell trait. J Ark Med Soc. 2012;108(12):270‐271. [PubMed] [Google Scholar]
  • 61. Dourakis SP, Alexopoulou A, Papageorgiou C, Kaloterakis A, Hadziyannis SJ. Acute chest syndrome in sickle‐cell trait; two case reports in persons of Mediterranean origin and review of the literature. Eur J Intern Med. 2004;15(4):248‐250. [DOI] [PubMed] [Google Scholar]
  • 62. Little I, Vinogradova Y, Orton E, Kai J, Qureshi N. Venous thromboembolism in adults screened for sickle cell trait: a population‐based cohort study with nested case‐control analysis. BMJ Open. 2017;7(3):e012665. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63. Folsom AR, Tang W, Roetker NS, et al. Prospective study of sickle cell trait and venous thromboembolism incidence. J Thromb Haemost. 2015;13(1):2‐9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64. Austin H, Lally C, Benson JM, Whitsett C, Hooper WC, Key NS. Hormonal contraception, sickle cell trait, and risk for venous thromboembolism among African American women. Am J Obstet Gynecol. 2009;200(6):620.e1‐620.e3. [DOI] [PubMed] [Google Scholar]
  • 65. Austin H, Key NS, Benson JM, et al. Sickle cell trait and the risk of venous thromboembolism among blacks. Blood. 2007;110(3):908‐912. [DOI] [PubMed] [Google Scholar]
  • 66. Noubiap JJ, Temgoua MN, Tankeu R, Tochie JN, Wonkam A, Bigna JJ. Sickle cell disease, sickle trait and the risk for venous thromboembolism: a systematic review and meta‐analysis. Thromb J. 2018;16:27. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67. Naik RP, Streiff MB, Haywood C Jr, Nelson JA, Lanzkron S. Venous thromboembolism in adults with sickle cell disease: a serious and under‐recognized complication. Am J Med. 2013;126(5):443‐449. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68. Caughey MC, Loehr LR, Key NS, et al. Sickle cell trait and incident ischemic stroke in the atherosclerosis risk in Communities study. Stroke. 2014;45(10):2863‐2867. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69. Caughey MC, Derebail VK, Key NS, et al. Thirty‐year risk of ischemic stroke in individuals with sickle cell trait and modification by chronic kidney disease: the atherosclerosis risk in communities (ARIC) study. Am J Hematol. 2019;94(12):1306‐1313. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70. Olaniran KO, Eneanya ND, Allegretti AS, Zhao SH, Achebe MM, Thadhani RI. Cardiovascular outcomes in African Americans with sickle cell trait and chronic kidney disease. Am J Nephrol. 2019;49(2):93‐102. [DOI] [PubMed] [Google Scholar]
  • 71. Marques MB, Singh N, Reddy VV. Out with the bad and in with the good; red cell exchange, white cell reduction, and platelet reduction. J Clin Apher. 2014;29(4):220‐227. [DOI] [PubMed] [Google Scholar]
  • 72. Boissier F, Bagate F, Schmidt M, et al. Extracorporeal life support for severe acute chest syndrome in adult sickle cell disease: a preliminary report. Crit Care Med. 2019;47(3):e263‐e265. [DOI] [PubMed] [Google Scholar]
  • 73. Alashkar F, Herbstreit F, Carpinteiro A, et al. Veno‐venous extracorporeal membrane oxygenation in adult patients with sickle cell disease and acute chest syndrome: a single‐center experience. Hemoglobin. 2020;44(2):71‐77. [DOI] [PubMed] [Google Scholar]
  • 74. Al‐Sawaf O, Kohler P, Eichenauer DA, Boll B, Kochanek M, Shimabukuro‐Vornhagen A. Management of an adult patient with sickle cell disease and acute chest syndrome by veno‐venous extracorporeal membrane oxygenation. Ann Hematol. 2019;98(3):789‐791. [DOI] [PubMed] [Google Scholar]
  • 75. Stevens EM, Patterson CA, Tchume‐Johnson T, et al. Parental attitudes towards prenatal genetic testing for sickle cell disease. J Pediatr Hematol Oncol. 2019;41(8):579‐585. [DOI] [PubMed] [Google Scholar]

Articles from European Journal of Haematology are provided here courtesy of Wiley

RESOURCES